PAVmed (PAVM) subsidiary Lucid Diagnostics (LUCD) said Wednesday it won a contract from the US Department of Veterans Affairs for its EsoGuard esophageal DNA test for esophageal precancer testing.

Financial terms of the contract were not disclosed.

The contract includes pre-negotiated pricing for the test that matches the established Medicare payment rate determined by the Centers for Medicare & Medicaid Services, enabling access through a single, national procurement framework, the company said.

Shares of PAVmed and Lucid Diagnostics were up 180% and 29% respectively in recent premarket activity Wednesday.